Valuation — not yet established
No valuation for Adaptilens is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($19.2M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Adaptilens
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Apr 2024 | Early Stage VC | $7.0M | ▮ | ▮ |
| Mar 2023 | Debt | $1.6M | ▮ | ▮ |
How Adaptilens's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Adaptilens, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Adaptilens raised?
- Adaptilens has raised $19.2M in total funding across 2 recorded rounds.
- When did Adaptilens last raise?
- Adaptilens last raised in Apr 2024 (Early Stage VC), raising $7.0M.